Orchid Pharma has received approval by the United States Food and Drug Administration (USFDA) for its novel invention, �Enmetazobactam`. This development comes in close succession to the recent recommendation for approval by the European Medicines Agency (EMA). Enmetazobactam is the first completely invented-in-India Beta Lactamase Inhibitor. This USFDA approval paves the way for the introduction of Enmetazobactam in the United States, the largest pharmaceutical market in the world. The product is expected to be launched within the next couple of quarters in the US market. This New Drug Approval (NDA) allows the use of Exblifep (Cefepime and Enmetazobactam) as an injection for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex. Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA. It is a significant development in addressing the global need for affordable and efficacious drugs to combat Anti-Microbial Resistance (AMR). Powered by Capital Market - Live News

Net profit of Orchid Pharma rose 287.75% to Rs 29.43 crore in the quarter ended December 2023 as against Rs 7.59 crore during the previous quarter ended December 2022. Sales rose 38.08% to Rs 220.59 crore in the quarter ended December 2023 as against Rs 159.76 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales220.59159.76 38 OPM %16.048.55 - PBDT39.4614.91 165 PBT30.196.73 349 NP29.437.59 288 Powered by Capital Market - Live News

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 8 February 2024.Powered by Capital Market - Live News

Orchid Pharma announced that CARE has assigned/ revised the credit rating on bank facilities of the company to CARE A-;Stable/ CARE A2 from CARE BBB; Stable / CARE A3+. Powered by Capital Market - Live News

Net profit of Orchid Pharma reported to Rs 19.80 crore in the quarter ended September 2023 as against net loss of Rs 5.39 crore during the previous quarter ended September 2022. Sales rose 20.28% to Rs 198.76 crore in the quarter ended September 2023 as against Rs 165.25 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales198.76165.25 20 OPM %11.7310.78 - PBDT27.8614.44 93 PBT20.02-3.32 LP NP19.80-5.39 LP Powered by Capital Market - Live News